Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRα-high and AZD5335 Versus Investigator's Choice Chemotherapy in FRα-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01)

NCT07218809 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07218809
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07218809 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRα-high and AZD5335 Versus Investigator's Choice Chemotherapy in FRα-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01)
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Recruiting
Start date
December 29, 2025
Completion date
December 27, 2029
Enrollment
1,100 (estimated)
Sites
299

Conditions

As the registry lists them; a condition with its own page is linked.

epithelial ovarian cancer